Mission Street, a specialist investor, developer and operator for the science and innovation sector, and BGO, a global real estate investment manager, have signed biotechnology company Nucleome Therapeutics at what they said is central Oxford’s first purpose-built commercial science scheme.
Mission Street and BGO Secure Biotech Group in First for Oxford City Centre Science
Nucleome Taking 20,000 Square Feet in Oxford’s West End
By Paul Norman
CoStar News
July 16, 2024 | 8:58 AM
RELATED ARTICLES
This news story is available exclusively to CoStar subscribers.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In
IN THIS ARTICLE
- Companies
- Bentall Green Oak
Real Estate